In a Phase 2 trial last year, a 9 mg dose of eloralintide achieved up to 20% weight reduction compared with a placebo
not FDA-approved as of June 2026
The glutathione S-transferases: their role in detoxification and toxification of xenobiotics
TMAO and CVD-related diseases In addition to CVDs, TMAO promotes numerous related diseases, such as diabetes, CKD, etc., which have a burden of cardiovascular complications (133, 134)
A dermonutrient containing special collagen peptides improves skin structure and function: a randomized, placebo-controlled, triple-blind trial using confocal laser scanning microscopy on the cosmetic effects and tolerance of a drinkable collagen supplement
It is produced through an enzyme called tyrosinase